Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy.

[1]  T. Ishizuka,et al.  Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer , 2022, Scientific reports.

[2]  S. Gerum,et al.  High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC , 2022, Cancers.

[3]  D. Visvikis,et al.  Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0 , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  Lixia Zhang,et al.  Influencing Factors and Prognostic Value of 18F-FDG PET/CT Metabolic and Volumetric Parameters in Non-Small Cell Lung Cancer , 2021, International journal of general medicine.

[5]  Tso-fu Wang,et al.  Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis , 2021, Diagnostics.

[6]  S. Gerum,et al.  Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis , 2021, Current oncology.

[7]  C. Belka,et al.  PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  S. Gerum,et al.  Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single‐center retrospective analysis , 2021, Thoracic cancer.

[9]  D. Gomez,et al.  An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer , 2021, Advances in radiation oncology.

[10]  J. Darcourt,et al.  Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study , 2020, Journal for ImmunoTherapy of Cancer.

[11]  Sonja Adebahr,et al.  Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. , 2020, The Lancet. Oncology.

[12]  Kunihiko Kobayashi,et al.  Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer , 2020, Journal of clinical medicine.

[13]  Nitin Ohri,et al.  18F-Fluorodeoxyglucose PET in Locally Advanced Non-small Cell Lung Cancer: From Predicting Outcomes to Guiding Therapy. , 2020, PET clinics.

[14]  Jin-Hyoung Kang,et al.  Prognostic value of 18F‐FDG PET parameters in patients with locally advanced non‐small cell lung cancer treated with induction chemotherapy , 2019, Asia-Pacific Journal of Clinical Oncology.

[15]  J. Sonke,et al.  Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  F Levi,et al.  European cancer mortality predictions for the year 2019 with focus on breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Debus,et al.  Re-irradiation in locally recurrent lung cancer patients , 2019, Strahlentherapie und Onkologie.

[18]  M. McLay,et al.  Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. , 2019, Current oncology.

[19]  Shau-Hsuan Li,et al.  Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis , 2018, Scientific Reports.

[20]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[21]  J. Neal,et al.  Prognostic Value of Pretreatment FDG‐PET Parameters in High‐dose Image‐guided Radiotherapy for Oligometastatic Non–Small‐cell Lung Cancer , 2018, Clinical lung cancer.

[22]  Philippe Lambin,et al.  F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study , 2018 .

[23]  G. Hanna,et al.  Re-irradiation for Locally Recurrent Lung Cancer: Evidence, Risks and Benefits. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

[24]  A. Bezjak,et al.  Serial 4DCT/4DPET imaging to predict and monitor response for locally-advanced non-small cell lung cancer chemo-radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Julian C. Hong,et al.  Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  S. Kalnicki,et al.  18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. , 2017, International journal of radiation oncology, biology, physics.

[27]  F. Sedlmayer,et al.  DART-bid for loco-regionally advanced NSCLC , 2017, Strahlentherapie und Onkologie.

[28]  M. Massaccesi,et al.  The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy , 2017, Radiation oncology.

[29]  Toshiaki Takahashi,et al.  Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study , 2016, Radiation Oncology.

[30]  R. Subramaniam,et al.  The Current and Evolving Role of PET in Personalized Management of Lung Cancer. , 2016, PET clinics.

[31]  S. Houshmand,et al.  PET-Based Thoracic Radiation Oncology. , 2016, PET clinics.

[32]  H. Popper.  Progression and metastasis of lung cancer , 2016, Cancer and Metastasis Reviews.

[33]  R. Rami-Porta,et al.  Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data , 2015, European Respiratory Journal.

[34]  S. Hyun,et al.  Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. , 2015, AJR. American journal of roentgenology.

[35]  Kyoungjune Pak,et al.  Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  Corinne Faivre-Finn,et al.  High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. , 2014, The Lancet. Oncology.

[37]  O. van Gómez López,et al.  Heterogeneity in [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Non–Small Cell Lung Carcinoma and Its Relationship to Metabolic Parameters and Pathologic Staging , 2014, Molecular imaging.

[38]  You Lu,et al.  Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local Control in Non–Small-Cell Lung Cancer Receiving Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  Max Dahele,et al.  High-dose, conventionally fractionated thoracic reirradiation for lung tumors. , 2014, Lung cancer.

[40]  Jeffrey D Bradley,et al.  Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  W. Oyen,et al.  18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy , 2013, The Journal of Nuclear Medicine.

[42]  Steven F Petit,et al.  Reirradiation and stereotactic radiotherapy for tumors in the lung: dose summation and toxicity. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  E. Yorke,et al.  Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT) , 2013, Radiation oncology.

[44]  Hao Zhang,et al.  Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer , 2013, International Journal of Computer Assisted Radiology and Surgery.

[45]  F. Tanaka,et al.  Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients. , 2012, Lung cancer.

[46]  B. Jeremic,et al.  Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. , 2011, International journal of radiation oncology, biology, physics.

[47]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[48]  P. Lambin,et al.  Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[49]  D. Gomez,et al.  Special topics in immunotherapy and radiation therapy: reirradiation and palliation. , 2007, Translational lung cancer research.

[50]  T. Tada,et al.  Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy , 2005, International Journal of Clinical Oncology.

[51]  G. Jiang,et al.  Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial. , 2003, International journal of radiation oncology, biology, physics.

[52]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[53]  T. Nakajima,et al.  Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[54]  Hideaki Takahashi,et al.  Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma. , 2018, Auris, nasus, larynx.

[55]  B. Loo,et al.  Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235 , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  R. Perez-soler,et al.  Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer. , 2015, Lung cancer.

[57]  Vitali Moiseenko,et al.  Radiation dose-volume effects in the heart. , 2010, International journal of radiation oncology, biology, physics.